Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Preveceutical Medical Inc PRVCF


Primary Symbol: C.PREV

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based... see more

Recent & Breaking News (CSE:PREV)

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

Newsfile May 21, 2019

Cutting Edge Cannabinoid Cancer Treatment Enters Final Stage

Proactive Investors April 30, 2019

IIROC Trade Resumption - PREV

Canada NewsWire April 17, 2019

PreveCeutical Partnership Leads to Two New Patent Filings

Newsfile April 17, 2019

IIROC Trading Halt - PREV

Canada NewsWire April 16, 2019

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

Newsfile April 15, 2019

PreveCeutical Scorpion Venom Cancer Study Continued Success

Stockhouse Editorial April 10, 2019

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model

Newsfile April 10, 2019

PreveCeutical Announces Default Judgment Against JCN Capital Corp.

Newsfile April 8, 2019

IIROC Trading Halt - PREV

Canada NewsWire April 5, 2019

IIROC Trade Resumption - PREV

Canada NewsWire April 5, 2019

Retraction to News Release dated April 4, 2019

Newsfile April 4, 2019

IIROC Trading Halt - PREV

Canada NewsWire April 4, 2019

Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project

Newsfile April 4, 2019

PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.

Newsfile March 25, 2019

PreveCeutical: Positive Results from Venom for Brain Cancer

Stockhouse Editorial March 11, 2019

PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model

Newsfile March 11, 2019

PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President

Featured Press Release February 13, 2019

PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President

Newsfile February 13, 2019

PreveCeutical Announces Closing of Non-Brokered Private Placement

Newsfile February 12, 2019